Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First human tests for groundbreaking malaria vaccine

NCT ID NCT02658253

Summary

This study tested the safety and immune response of a new vaccine designed to protect pregnant women from placental malaria. It involved 68 healthy adult women from France and Burkina Faso who received three doses of the experimental vaccine. The main goal was to check for side effects and see if the vaccine triggered a protective immune response.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CIC 1417

    Paris, 75679, France

  • CNRFP

    Ouagadougou, BP 2208, Burkina Faso

Conditions

Explore the condition pages connected to this study.